Lisa Gora, James Boiani, and Marylana Helou, Members of the Firm, co-present “Legal and Regulatory Challenges in Psychedelic Research and Commercialization," Part 2 of a webinar series hosted by the Blue Cross Blue Shield Association.

In Part 2 of this two-part series, the panel discusses how psychedelic drugs are gaining increased favor as potential treatments for a number of psychiatric conditions.

Recent data has shown promise for the use of MDMA, psilocybin, and LSD to treat depression and trauma-based conditions, not to mention the increasingly widespread use of FDA-approved ketamine for treatment refectory depression. As with MDMA, the FDA has designated a psilocybin analog as a "breakthrough therapy” – granted to promising novel therapies that preliminary data suggests may provide advances over available treatments. Also, while two states (Colorado and Oregon) and a number of cities across the US have decriminalized the use of psilocybin for therapeutic and non-therapeutic purposes, these currently remain illegal at the federal level as Schedule 1 substances (with “no currently accepted medical use and a high potential for abuse”) under the Controlled Substances Act.

Conducting research on psychedelic drugs raises unique ethical, legal, and regulatory challenges. When do FDA regulations apply and what is FDA’s position with respect to psychedelic research? How should researchers resolve conflicting federal and state laws? What other legal and regulatory concerns must researchers consider? Also, taking products from clinical investigation to market requires navigating further hurdles in terms of trial designs to establish efficacy, quantifying and managing safety concerns, and building a framework for reimbursement that can succeed. This session will address these issues, providing some key points of consideration relevant to development and commercialization of these promising therapies.

For more information, visit the BCBS Association event website.

Event Detail

1:00 p.m. – 2:00 p.m. ET


Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.